Human Monoclonal Antibodies Neutralizing Influenza H5N1 via HA2 Epitope Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines are ineffective against H5N1 influenza virus infections, posing a significant public health risk due to the virus's high pathogenicity and ability to cross the species barrier, leading to potential epidemics and pandemics.
Innovation Solution
Development of human binding molecules, such as monoclonal antibodies, that specifically bind to the H5N1 virus and neutralize its activity, with the ability to cross-react with other influenza subtypes, providing prophylactic, therapeutic, and diagnostic capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are used, then protection against common influenza strains is provided, but they are ineffective against H5N1 influenza virus infections
Solution Approach 1:
The patent develops binding molecules that recognize conserved epitopes in the HA2 domain of hemagglutinin across multiple influenza subtypes including H1, H2, H5, H6, and H9. This universal binding capability allows a single therapeutic agent to protect against diverse influenza strains, resolving the contradiction between vaccine effectiveness for common strains and adaptability to H5N1 and other subtypes.
2Reliability
If highly specific binding molecules are developed for H5N1, then neutralizing activity against H5N1 is achieved, but cross-reactivity with other influenza subtypes is reduced
Solution Approach 1:
The patent targets a specific local region (the HA2 domain, particularly the fusion peptide region) that is conserved across influenza subtypes. By focusing binding activity on this localized conserved region rather than variable regions, the binding molecules achieve both high neutralizing activity against H5N1 and cross-reactivity with other subtypes, resolving the contradiction between specificity and versatility.
3Duration of action of moving object
If conventional vaccine strategies are pursued, then immunity against known strains is established, but protection against emerging high-pathogenicity strains like H5N1 is insufficient
Solution Approach 1:
The patent employs passive immunization with pre-formed binding molecules that provide immediate neutralizing activity against H5N1 and other high-pathogenicity strains. This preliminary action approach bypasses the slow process of active vaccine-induced immunity, providing rapid protection against emerging threats while the molecules' stable binding ensures sustained neutralization over time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The human binding molecules effectively neutralize H5N1 virus, offering protection and treatment options for individuals at risk, including those infected or potentially infected, and can be used to diagnose the virus, thereby mitigating the risk of outbreaks.
Implementation Method 1
human binding molecules capable of specifically binding to influenza virus H5N1 and exhibiting neutralizing activity against H5N1
Data Source
AI summary
Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are polynucleotides encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.